Zyprexa vs. Vraylar
See how Zyprexa and Vraylar compare on approved uses, dosing, side effects, and cost.
Key Takeaways
Zyprexa comes as a tablet, dissolving tablet, or injection, while Vraylar is only an oral capsule, but Vraylar adds major depressive disorder to its approved uses.
Both drugs carry a boxed warning about increased risk of death in older adults with dementia-related psychosis, so neither is approved for that use.
Zyprexa tends to cause more sedation and weight gain, while Vraylar is more likely to cause akathisia and restlessness, especially at higher doses.
Zyprexa vs. Vraylar Drug Summary
Zyprexa
Zyprexa (olanzapine) is an atypical antipsychotic used to treat schizophrenia and bipolar I disorder, including acute mania and, when combined with fluoxetine, depressive episodes. It comes as a standard tablet, a dissolving tablet, a short-acting injection for acute agitation, and a long-acting monthly injection called Relprevv.
Vraylar
Vraylar (cariprazine) is an atypical antipsychotic used to treat schizophrenia, bipolar I mania, bipolar depression, and major depressive disorder as an add-on to antidepressants. It comes only as an oral capsule taken once daily, and dose changes are spaced out because the drug and its active metabolites stay in the body for weeks.
Zyprexa vs. Vraylar Side Effects
Zyprexa
Vraylar
Zyprexa vs. Vraylar Dosage
Zyprexa
Vraylar
| STAGE | DOSE | WHEN |
| Starting dose | 5-10 mg once daily | At the start |
| Maximum dose | 2.5-10 mg per IM dose | If needed |
| Dose changes | 4 increases | As tolerated |
| STAGE | DOSE | WHEN |
| Starting dose | 1.5 mg once daily | Day 1 |
| Maximum dose | 1.5-3 mg once daily | If needed |
| Dose changes | 5 increases | As tolerated |
Zyprexa
| STAGE | DOSE | WHEN |
| Starting dose | 5-10 mg once daily | At the start |
| Maximum dose | 2.5-10 mg per IM dose | If needed |
| Dose changes | 4 increases | As tolerated |
Vraylar
| STAGE | DOSE | WHEN |
| Starting dose | 1.5 mg once daily | Day 1 |
| Maximum dose | 1.5-3 mg once daily | If needed |
| Dose changes | 5 increases | As tolerated |
Zyprexa vs. Vraylar Indications
Zyprexa
Zyprexa is FDA-approved for schizophrenia in adults and adolescents, and for bipolar I mania alone or with lithium or valproate. It also covers maintenance treatment of bipolar I disorder, acute agitation, and bipolar depression when combined with fluoxetine. Off-label, doctors sometimes use it to help prevent nausea and vomiting caused by chemotherapy.
Schizophrenia (adults and adolescents 13-17)
Bipolar I mania, alone or with lithium/valproate
Maintenance treatment of bipolar I disorder
Bipolar depression, combined with fluoxetine
Vraylar
Vraylar is FDA-approved for schizophrenia in adults and adolescents aged 13 and older, and for manic or mixed episodes of bipolar I disorder in patients 10 and older. It also treats depressive episodes of bipolar I disorder in adults and, as an add-on to antidepressants, major depressive disorder in adults. It is taken as a single daily capsule across most of its approved conditions.
Schizophrenia (adults and adolescents 13+)
Bipolar I manic or mixed episodes (ages 10+)
Bipolar I depressive episodes (adults)
Adjunctive therapy for major depression (adults)
Zyprexa vs. Vraylar Pros and Cons
Zyprexa
Zyprexa has decades of real-world use across schizophrenia and bipolar disorder, plus a long-acting injectable option for patients who struggle with daily pills. It carries a higher risk of weight gain and sedation than many newer antipsychotics, and its long-acting injection requires an in-office observation period.
Pros
Available as a long-acting monthly injection (Relprevv) for adherence
Broad, well-established track record dating back to 1996
Short-acting IM option specifically for acute agitation
Lower list price: roughly $440 to $900 per month before insurance
Cons
Higher risk of significant weight gain and metabolic changes
Very sedating for many patients (somnolence up to 52%)
Relprevv injection requires a 3-hour monitored observation period
Only treats depression when paired with fluoxetine, not on its own
Vraylar
Vraylar's partial-agonist mechanism gives it a depression-focused label, including approval as an add-on for major depressive disorder that Zyprexa lacks. It carries a higher risk of akathisia and restlessness, and dose changes take weeks to fully show up because of its long half-life.
Pros
Only one of these two approved as an add-on for major depressive disorder
Trial data show under 3% of patients had significant weight gain
Simple once-daily capsule with no injectable-monitoring requirements
Available in six capsule strengths for finer dose adjustments
Cons
Higher rates of akathisia and restlessness, especially at bipolar mania doses
No long-acting injectable option for patients who miss daily doses
Long half-life means dose changes take weeks to fully assess
Higher list price: roughly $1,300 to $1,400 per month before insurance
Common Symptoms and Related Diseases You Can Explore
Explore a range of common symptoms the Doctronic Symptom Checker can help you understand.